At a glance
ClinicalIndex Comparison RecordN/AUnknown· 300 target
Drug / intervention
Niraparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational, Non-interventional Study of Niraparib Maintenance Treatment in Patients With Ovarian Cancer After Frontline Platinum-based Chemotherapy
In Brief
An observational study evaluating Niraparib for Epithelial Ovarian Cancer. Targeting 300 participants.
Detailed Summary
This is an open-label, single-arm, multi-center、non-interventional real-world study, which evaluate treatment pattern, safety and efficacy of Niraparib as first-line maintenance treatment for Chinese patient with newly diagnosed ovarian cancer , fallopian tube cancer, and primary peritoneal cancer in real world clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEpithelial Ovarian Cancer
Countries--
Collaborators--
Timeline
N/AUnknownOverdue
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionAug 2022
Study CompletionFeb 2025
TodayJul 2026
First PostedAug 2, 2021
Enrollment StartAug 10, 2021
Primary CompletionAug 31, 2022
Study CompletionFeb 28, 2025
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 4.9 years ago
Interventions
Niraparibdrug
Usage following drug insert is recommended